American visceral leishmaniasis (kala-azar) in hospitalized children from an endemic area

Leishmaniose visceral americana (calazar) em crianças hospitalizadas de área endêmica

Luís C. Rey, Ceci V. Martins, Hildenia B. Ribeiro, Aldo A. M. Lima

Abstract

Objective: To study epidemiological and clinical aspects of American visceral leishmaniasis in hospitalized children in Ceará, Brazil.

Methods: A retrospective and observational study was carried out with children suffering from American visceral leishmaniasis admitted to Hospital Infantil Albert Sabin in Fortaleza. Medical records were reviewed consistently. Inclusion criteria were children with amastigote-positive smears in bone marrow or in splenic aspirates, or a positive Leishmania sp immunofluorescence assay.

Results: From January 1995 to December 2002, 450 children with American visceral leishmaniasis were identified, accounting for 9 to 27% of all reported cases in Ceará in that period, with peak hospitalization rates in 1995 and 2000. The mean age was 4.4 years (12% < 1 year and 65% < 5 years of age). The overall male: female ratio was 1.1 and 1.48 in children > 5 year (p = 0.04). The main clinical complaints on admission were fever (96%), pallor (90%) and abdominal swelling (75%). Clinical cure was defined as the absence of fever, regression of splenic and hepatic enlargement and of pancytopenia. Overall mortality was 9.2% and 21.2% in patients younger than one year. Malnutrition, edema, bleeding, jaundice, and concomitant infections were related to higher mortality.

Conclusions: Cases of American visceral leishmaniasis spiked with a 5-year interval, and affected most under-five urban children. Mortality was related to low age, signs of severe disease and concomitant infection.


Introduction

American visceral leishmaniasis (AVL) is an expanding anthroponosis in Brazil. Over 3,000 new cases are reported every year, in 19 out of 23 states. The Northeast region (nine states) accounts for 70-90% of all patients, mostly in the states of Bahia, Ceará, Piauí and Maranhão, with an incidence rate of 25 cases per 100,000 inhabitants. Urban transmission to humans, assessed through clinical reports or serological surveys, has continually increased in the last four decades; in most regions where AVL transmission is present, epidemic outbreaks occur every 5 to 10 years.
The shift of *Leishmania* (*L.*) *chagasi* transmission from rural to urban and periurban areas has been explained by migration of impoverished families of peasants with infected dogs.2-5 Cyclic drought periods related to El Niño are also implicated in the ecological impact of deforestation and new human riverbank settlements.5-7 *Lutzomyia* (*L*) *longipalpis* (Diptera: Psychodidae) became adapted to urban houses and to the overcrowding conditions of slums, thus increasing its efficacy as the vector of *L. chagasi*.8 Cyclic urban AVL outbreaks occurred in the city of Teresina in the years 1980 to 1986 and 1992 to 19964,9 and in other state capitals such as São Luís,10 Natal11 and Belo Horizonte.12 Other Brazilian towns have also experienced periurban burdens of AVL.13,14

Clinical reports of AVL in Ceará are scarce and most were published more than 30 years ago.2-3 AVL has been described as a severe disease characterized by malnutrition, extreme pallor, abdominal enlargement with edema, bleeding, jaundice, chronic or persistent diarrhea and respiratory infections. Milder disease often was unrecognized at the local level and still is, which delays proper diagnosis and treatment. This updated hospital-based clinical study in an endemic area is therefore necessary for clinicians at the primary and local level of health care. The aim of the study was to analyze epidemiological and clinical aspects of AVL in children admitted to a reference (tertiary-care) public hospital in Fortaleza.

**Patients and methods**

The study was conducted in Fortaleza, the state capital of Ceará, Northeastern Brazil. Hospital Infantil Albert Sabin (HIAS) is a tertiary-care pediatric facility with nearly 200 beds and qualified specialists.

All infants or children admitted to HIAS with an amastigote-positive bone marrow or splenic aspirate were included in the study. Those with positive *Leishmania* immunofluorescence assay findings were also included. Any patients who were admitted to HIAS and were infected with AVL but did not reside in the state of Ceará were excluded.

Handwritten medical records were used to screen AVL patients treated between 1995 and 1998, and a computerized database system was used to screen those treated between 1999 and 2002. All selected medical records were consistently reviewed, and a structured protocol form was employed to collect epidemiological data (age, sex, place of residence, housing conditions) and clinical data (duration of signs and symptoms, physical examination, diagnostic tests, laboratory data, treatment and outcome). Visceral enlargement (in cm) was measured from the lower rib to the distal edge of the affected organ. Prothrombin activity (in %) was recorded as indicated by the manufacturer (Option, bioMérieux Brasil, Rio de Janeiro, Brazil). The study protocol was approved by the Ethics and Research Committee of the referred hospital.

The data were validated by reviewing 20% of the selected hospital files and by double-typing the data entries into an IBM-compatible computer. Epi-Info 6.0415 and SPSS software were used for the statistical analysis. Continuous variables such as age, weight, liver and spleen measurements, and laboratory data, were described by means and 95% confidence intervals (95%CI), when appropriate, and compared using Student’s t-test for independent or dependent variables. Paired data were measured before and after treatment. Contingency tables containing categorical variables, such as sex and outcome, and dichotomized continuous variables were analyzed through the chi-square test or Fisher’s exact test, when necessary, and the odds ratio was calculated using Cornfield’s 95% confidence intervals. Stratified (bivariate) analyses of contingency tables were used to identify possible interactions among clinical findings (low age, jaundice, bleeding, edema, infection) and their association with hospital outcome (child’s death or discharge). In these particular situations, the Mantel-Haenszel-adjusted odds ratio was considered. In all cases, a p < 0.05 was considered as significant.

**Results**

From January 1995 to December 2002, 450 patients with confirmed AVL were admitted to HIAS in Fortaleza. The rate of confirmed cases in this facility varied from 9 to 27% of all cases reported in that state4 during the study period (Table 1). Peak hospitalization rates occurred in 1995 and between 1999 and 2000, decreasing in the subsequent years.

### Table 1 - Cases of American visceral leishmaniasis reported in the State and confirmed at Hospital Infantil Albert Sabin, 1995-2002

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>HIAS</td>
<td>98</td>
<td>31</td>
<td>18</td>
<td>43</td>
<td>90</td>
<td>97</td>
<td>49</td>
<td>24</td>
<td></td>
</tr>
<tr>
<td>Ceará (CE)*</td>
<td>490</td>
<td>220</td>
<td>130</td>
<td>158</td>
<td>421</td>
<td>496</td>
<td>396</td>
<td>259</td>
<td>1</td>
</tr>
<tr>
<td>HIAS/CE (%)</td>
<td>(20)</td>
<td>(14)</td>
<td>(14)</td>
<td>(27)</td>
<td>(21)</td>
<td>(20)</td>
<td>(12)</td>
<td>(9)</td>
<td></td>
</tr>
</tbody>
</table>

* Source: COVEV/CGDT/DEVEP/SVS-MS.1

† Preliminary data.
Ninety-seven children lived in Fortaleza (22%) and 120 (27%) in six towns in the metropolitan area of Fortaleza (MAF): Caucaia, Eusébio, Maranguape, Pacajus, Maracanaú and Pacatuba. The number of towns with hospital admissions due to AVL was highest in 1995 and 2000 (98 and 97 out of 184 towns, respectively) and lowest in 1997 (only 18 towns).

No relative increase was observed throughout the study period in AVL patients from Fortaleza and from the MAF ($\chi^2 = 9.49$, df = 7, $p = 0.22$) (Figure 1). However, there was a significant increase in the hospital admission of AVL children living in all urban areas in the study period ($\chi^2 = 18.08$, df = 7, $p = 0.01$) (Figure 2).

Of the 438 families for which information was available, 255 (58%) lived in brick houses and 183 (42%) in adobe or mud-and-stick houses (t-test $p < 0.001$). By comparing the ratio of adobe vs brick houses in 1995 and 2000 (outbreak years), it is observed that the proportion shifted from 1.07 (48/45) to 0.53 (33/62), showing a significant increase in the number of brick houses ($\chi^2 = 5.46$, $p = 0.01$), which indicates an increase in the urban origin of our patients.

The mean age of the 450 AVL cases was 54 months (95%CI: 50-57 months), (57 months for boys and 50 for girls) ($p < 0.05$). Patients were younger than one year (12% or 52/450) and younger than five (65% or 294/450).

Fifty-three percent (240/450) of the patients were male and 47% were female (male:female ratio= 1.1). The male:female ratio was as high as 1.48 (t-test $p = 0.04$) in children older than five years.

Tables 2 and 3 show the nutritional status and clinical findings regarding AVL patients admitted to HIAS. The average length of the disease prior to hospital admission was 7.9 weeks (95%CI: 7.1 to 8.7 weeks). Clinical manifestations of severe disease (bleeding, edema, jaundice) were not associated with longer duration of the disease. Infants less than one year of age showed more hemorrhagic disorders than older patients ($\chi^2 = 10.0$, $p = 0.0007$).

Non-specific complaints were cough (51 children), diarrhea (41), shortness of breath (13), limb and joint pain (six), febrile seizures (three), and alopecia (three cases). Community and nosocomial infections were detected in 49% of all patients. Patients younger than one year presented more infectious episodes than older patients ($\chi^2 = 5.0$, $p = 0.03$).

Before treatment, splenic enlargement was detected in 99% (436) of the 450 patients and liver enlargement in 95% (406) of the children; 25% of the patients had serum hemoglobin $< 5.0$ g/dl, 25% had a total leukocyte count $< 2,000/mm^3$, and 18% had a neutrophil count $< 500/mm^3$. 

Table 2 - Clinical aspects of American visceral leishmaniasis at HIAS, 1995-2002

<table>
<thead>
<tr>
<th>Nutritional status (n = 432)</th>
<th>n</th>
<th>%</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>(WAZ score) *</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Well nourished</td>
<td>168</td>
<td>39</td>
<td>34-44</td>
</tr>
<tr>
<td>Mild malnutrition</td>
<td>153</td>
<td>35</td>
<td>31-40</td>
</tr>
<tr>
<td>Moderate malnutrition</td>
<td>81</td>
<td>19</td>
<td>15-23</td>
</tr>
<tr>
<td>Severe malnutrition</td>
<td>30</td>
<td>7</td>
<td>5-10</td>
</tr>
<tr>
<td>Symptoms and signs † (n = 450)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fever</td>
<td>432</td>
<td>96</td>
<td>94-98</td>
</tr>
<tr>
<td>Pallor</td>
<td>387</td>
<td>86</td>
<td>82-89</td>
</tr>
<tr>
<td>Abdominal swelling</td>
<td>342</td>
<td>76</td>
<td>72-80</td>
</tr>
<tr>
<td>Anorexia</td>
<td>221</td>
<td>49</td>
<td>44-54</td>
</tr>
<tr>
<td>Weakness</td>
<td>210</td>
<td>47</td>
<td>42-51</td>
</tr>
<tr>
<td>Weight loss</td>
<td>197</td>
<td>44</td>
<td>39-49</td>
</tr>
<tr>
<td>Edema</td>
<td>128</td>
<td>28</td>
<td>24-33</td>
</tr>
<tr>
<td>Hemorrhage</td>
<td>42</td>
<td>9</td>
<td>7-13</td>
</tr>
<tr>
<td>Jaundice</td>
<td>33</td>
<td>7</td>
<td>5-10</td>
</tr>
</tbody>
</table>

* WAZ: weight-for-age z score; well nourished: WAZ $\geq$ -1; mild malnutrition: -1 > WAZ $\geq$ -2; moderate: -2 > WAZ $\geq$ -3; severe: WAZ < -3.
† Cumulative data.
Of 445 bone marrow aspirates performed, 73% were amastigote-positive (329 smears). A second bone marrow aspirate was performed in 53 out of 116 amastigote-negative smears, and 53% (28) were also positive for *Leishmania*. In 31 amastigote-negative bone marrows, a splenic aspirate was performed, and 81% (24 specimens) were amastigote-positive. The remaining 71 patients had a confirmed diagnosis of AVL by *Leishmania*-specific immunofluorescence assay (IFA). The IFA was performed in 179 patients during their hospital stay, and 95 out of 111 amastigote-positive blood marrow or splenic smears were seropositive (sensitivity of 86%). Three cases of amastigote-negative bone marrow and splenic aspirate were diagnosed only through *Leishmania*-specific IFA. The mean hospital stay before therapy began was 6 days (median: 5 days), but a treatment delay of 45 days was detected.

Once AVL was confirmed, 98% (439/450) of the children were treated with meglumine antimoniate; 29% also received allopurinol as an adjuvant to antimoniate. After a mean 25-day course of pentavalent antimony, only 4% (18 patients) required amphotericin B as second-line treatment. Of these, two died soon after amphotericin B therapy was started. A total of 388 patients (91%) responded successfully to treatment (cured or clinically improved). Children admitted but not treated constituted 6.2% (28) of the patients. Five of these patients died before any specific treatment was started, and 23 were transferred to another hospital. The mean hospital stay at the HIAS was 28 days.

Before or during hospitalization, 220 children (49%, 95%CI: 44-54%) presented at least one infectious episode. The most frequent infections were pneumonia (108 cases), sepsis (32), otitis media (27), infectious dermatitis (25) and diarrhea (four cases).

### Infection
All patients improved their clinical and laboratory conditions with the treatment (Table 3). The mean decrease in splenic and hepatic size amounted to 48% and 32%, respectively. Hemoglobin level rose 44%, total leukocyte count 48%, neutrophils 61%, platelets 58% and prothrombin activity increased 22% at hospital discharge; a 24 and 7% reduction was observed for ESR and serum globulin levels, respectively.

AVL mortality was 8.7% (39/450) (95%CI: 6.3-11.8) in the study period. Mortality was 21.2% in children younger than one year and 7.6% in children older than one year [Mantel-Haenszel (MH)-adjusted OR = 3.49; 95%CI: 1.5 - 8.0, p < 0.001]. Moderate to severe malnutrition [measured by weight-for-age (WAZ) z-score < -2] was related to a 13.2% mortality rate, compared to 7.0% in children with WAZ > -2 z-scores, (MH-adjusted OR = 2.04; 95%CI: 0.93-4.36, p = 0.04). Other clinical findings on admission related to hospital mortality were: jaundice (MH-adjusted OR = 3.76, 95%CI: 1.41-9.76, p = 0.002), hemorrhage (MH-adjusted OR = 7.22, 95%CI: 3.14-16.57, p < 0.001), edema (MH-adjusted OR = 3.07, 95%CI: 1.49-6.35, p < 0.001), and community or nosocomial infection (MH-adjusted OR = 3.34, 95%CI: 1.5 - 7.6, p < 0.001). The mean hospital stay of patients who died was 14 days, thus shorter than the 28 days of discharged children (t-test p < 0.001).

### Table 3 - Clinical aspects and laboratory mean values of children at admittance and discharge

<table>
<thead>
<tr>
<th>Clinical and laboratory aspects</th>
<th>n of pairs</th>
<th>Mean value at admittance</th>
<th>Mean value at discharge</th>
<th>t-paired p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Visceral enlargement (cm) *</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Splenomegaly</td>
<td>358</td>
<td>7.9</td>
<td>4.1</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Hepatomegaly</td>
<td>348</td>
<td>4.4</td>
<td>3.1</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Hemoglobin (g/dl)</td>
<td>374</td>
<td>6.2</td>
<td>8.9</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Total leukocytes/mm³</td>
<td>376</td>
<td>3,281</td>
<td>6,314</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Neutrophils/mm³</td>
<td>366</td>
<td>1,174</td>
<td>3,015</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Platelets/mm³</td>
<td>362</td>
<td>125,760</td>
<td>302,470</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>ESR † (first hour)</td>
<td>272</td>
<td>86</td>
<td>65</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Prothrombin activity (%)</td>
<td>263</td>
<td>68.9</td>
<td>89.9</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Serum globulin (g/dl)</td>
<td>327</td>
<td>4.2</td>
<td>3.9</td>
<td>0.005</td>
</tr>
</tbody>
</table>

* From lower rib to distal edge of the organ.  † Erytrocyte sedimentation rate.
Causes of death in 39 patients were: infection in 29 cases (74%), hemorrhage in six (15%), hepatic failure in three (8%) and cardiac arrhythmia in one case (3%). Fatal infections were septicemia and pneumonia.

Discussion

Retrospective studies using medical records of children with AVL can provide useful epidemiological and clinical data, particularly in endemic areas, and should be performed on a regular basis. The cyclic increase in AVL cases at HIAS from 1995 to 2002 suggests that *L. chagasi* transmission and the burden of disease is out of control in that state. Also, the high rate of patients in a single facility should be a matter of concern and may indicate a high rate of unreported cases throughout the state, or concentration of AVL management in a few reference health facilities, mainly in Fortaleza. In states where AVL is uncommon as São Paulo, Bahia, and Federal District of Brasília, the presence of AVL patients from endemic areas of Brazil is frequent because of the local difficulties to receive appropriate care; the mean time of disease previous to hospital admission is 5.6 months in São Paulo, and 3 months in Brasilia and in São Luís (state of Maranhão).

Outbreaks of AVL have occurred in state capitals as Natal, where 60% out of 1,500 cases were reported in the state in 1991; differently, in our study, we were not able to identify a specific burden of the disease in Fortaleza, where 20% of our patients live. We have detected, however, a consistent increase in urban AVL in the state (59% of all hospitalized patients were urban settlers), as described in prospective studies. On the other hand, 72% of AVL patients treated in Brasilia dwell in rural areas, and most of them came from the state of Bahia.

At HIAS, in Ceará, AVL affected mainly children younger than five years, a finding reported since the 1980s; patients younger than five years corresponded to 49% in Natal, 64% in Maranhão, but only to 28% in Belo Horizonte, a new expanding area of AVL in Brazil. The high proportion of infants younger than one year old in our hospital (12%) could be explained by the indoor transmission of *L. chagasi* in urban and periurban areas, as in Belo Horizonte (5%) and in São Luís.

The severity of clinical findings is related to both a delay in providing medical assistance and to the young age of the patients. It appears that the shorter the duration of the disease, the better the clinical aspect of AVL. Children from a hyperendemic area of AVL in Jacobina showed less severe disease than patients admitted to the Teaching Hospital of Salvador. In São Paulo, the higher proportion of edema and jaundice in hospitalized patients is probably due to the long period of disease, as many patients live in other states, especially Bahia and Piauí.

As occurs in hospital-based series of children with AVL, the disease was clinically apparent. In community-based studies of endemic areas, serological screening for *Leishmania sp* revealed eight to 16 asymptomatic seropositive patients for each clinical case, which reflects the need of local surveillance and treatment as early as possible. According to our data, a poorer outcome was strongly related to severe clinical signs prior to admission.

Previous nutritional status is crucial for the clinical outcome of AVL. Moderate to severe malnutrition (weight-for-age z score below -2) in Ceará accounted for 9.2% in children < 5 years, and mild malnutrition (-1.9 to -1.0 z score), to 24% of these children. Our data show a higher rate of malnutrition compared to community-based studies, as reported in AVL cases admitted to hospitals in Brasilia and São Paulo. In Jacobina, Bahia, prospective studies showed that malnutrition was an important condition for the burden of clinical AVL as well as a consequence of long-term disease, and was less severe in early-diagnosed patients.

The diagnosis of AVL could be established earlier if more rapid and accurate tests for AVL were available. *Leishmania* culture is a time-consuming alternative (2 to 4 weeks), and time is crucial in advanced (severe) disease and for infants with AVL. *Leishmania* cultures are not routinely performed in Fortaleza, Natal, Sào Luís or Salvador.

The length of antimonials therapy varied from 20 to 40 days in Fortaleza. Assessment of cure in AVL is controversial. Amastigote-negative smears have low negative predictive values, and immunoassays will become negative months after treatment. Physical examination and improved laboratory findings are therefore important criteria for cure. Absence of fever, physical activity, recovery of appetite, and weight gain are indirect signs. A 50% decrease in splenic and (to a lesser degree) hepatic size, and a substantial increase in blood cell counts are crucial. In our series, the treatment with meglumine antimoniate showed a high cure rate and low toxicity, as also reported in Natal. In our study, the decrease in visceral swelling was less than 50%, although we were unable to obtain information on visceral measurements from many discharged patients, probably because they had little or no visceral enlargement.

Therapeutic failure with antimonials was seen in 15% of cases of an age-mixed group of patients in São Paulo, with different disease duration and treatment regimens. The concomitant use of allopurinol and antimony salt was frequent at HIAS in patients showing poor clinical improvement. However, no study on the efficacy of allopurinol in AVL has been published in Brazil, and protocols are necessary to validate the use of this drug in this condition.

Therapy with pentavalent antimony at the Teaching Hospital of Salvador showed to be effective after 30 days of treatment. In the endemic area of Jacobina, where clinical AVL is detected early, recovery is achieved with a 15-day treatment course.

The mean specific mortality rate in our study is similar to reports from other urban health centers as Belo Horizonte (8-17% mortality), São Paulo 7%, São Luís (6.7%), Natal (9%), and Brasilia (9.2%). In Bahia, mortality was 6% in local treatment of AVL in
To reduce AVL morbidity and mortality, it would be necessary to screen and treat AVL earlier, at the local or regional level. In this regard, rapid and simple diagnostic tests for clinical AVL, as recombinant K39 strip tests should be available. Clinical trials with oral miltefosine (hexadecylphosphocholine), a new and highly effective drug used to treat Indian kala-azar, should also be performed with AVL.

References


Corresponding author:
Luís C. Rey
Unidade de Pesquisa Clínica, Instituto de Biomedicina
Faculdade de Medicina, Universidade Federal do Ceará
Av. José Bastos, 3390 sala 90
CEP 60436-160 – Fortaleza, CE
Brazil
Phone: +55 (85) 9982.3925/261.1013
E-mail: reyfonte@secrel.com.br